Celastrol Inhibits the Growth of Ovarian Cancer Cells in vitro and in vivo

Li-Na Xu 1†, Na Zhao 1†, Jin-Yan Chen 2†, Piao-Piao Ye 1, Xing-Wei Nan 1, Hai-Hong Zhou 1, Qi-Wei Jiang 3, Yang Yang 3, Jia-Rong Huang 3, Meng-Ling Yuan 3, Zi-Hao Xing 3, Meng-Ning Wei 3, Yao Li 3, Zhi Shi 3* and Xiao-Jian Yan 1,4*

1 Department of Gynecology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China, 2 Department of Gynecology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, 3 Department of Cell Biology and Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University, Guangzhou, China, 4 Center for Uterine Cancer Diagnosis & Therapy Research of Zhejiang Province, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Zhejiang, China

Celastrol is a natural triterpene isolated from the Chinese plant Thunder God Vine with potent antitumor activity. However, the effect of celastrol on the growth of ovarian cancer cells in vitro and in vivo is still unclear. In this study, we found that celastrol induced cell growth inhibition, cell cycle arrest in G2/M phase and apoptosis with the increased intracellular reactive oxygen species (ROS) accumulation in ovarian cancer cells. Pretreatment with ROS scavenger N-acetyl-cysteine totally blocked the apoptosis induced by celastrol. Additionally, celastrol inhibited the growth of ovarian cancer xenografts in nude mice. Altogether, these findings suggest celastrol is a potential therapeutic agent for treating ovarian cancer.

Keywords: celastrol, reactive oxygen species, N-acetyl-cysteine, apoptosis, ovarian cancer

INTRODUCTION

Ovarian cancer is the most lethal gynecologic cancer and the fifth leading cause of female cancer-related deaths in the United States in 2018 (1). Because of the late stage diagnoses, the prognosis of ovarian cancer remains poor, despite advances in aggressive surgery and combination chemotherapy (2–4). Current treatments for ovarian cancer are far from satisfactory, therefore it is of considerable interest to develop novel therapeutic agents to improve the outcomes of ovarian cancer.

Celastrol is a natural triterpene isolated from the Chinese plant Thunder God Vine (Tripterygium wilfordii), which has been reported with a wide range of bioactivities, such as antitumor (5), anti-inflammatory (6), antidiabetic activities (7) and antihypertensive (8). Celastrol has shown the potent antitumor activity in various cancers including prostate, breast, liver, colon, and lung (9–13). Although celastrol is able to induce apoptosis and inhibit proliferation, migration and invasion in ovarian cancer cells in vitro (14–16), the effect of celastrol on the growth of ovarian cancer cells in vivo is still unknown. Here, we have comprehensively investigated the antitumor activity of celastrol in ovarian cancer cells in vitro and in vivo.

MATERIALS AND METHODS

Cells Lines and Reagents

The human ovarian cancer lines A2780 and SKOV3 were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml) and
streptomycin (100 ng/ml) at 37°C with 5% CO2 in a humidified incubator. Celastrol was purchased from Shanghai Tauto Biotechnology. N-acetyl-L-cysteine (NAC) and dihydroethidium (DHE) were purchased from Sigma-Aldrich. Methylthiazolyl diphenyl-tetrazolium bromide (MTT), propidium iodide (PI) and other chemicals were purchased from Shanghai Sangon Biotech. Anti-p27 (610241), Anti-Cyclin B1 (554177), and Anti-Cyclin E (51-1459GR) antibodies were from BD Biosciences. Anti-RAF1 (SC-133) antibodies were from Santa Cruz Biotechnology. Anti-PARP (9542), Anti-AKT (4691), Anti-pAKT S473 (4060), Anti-ERK (4695), Anti-pERK T202/T204 (4370), Anti-JNK (9252), Anti-pJNK T183/Y185 (4668), Anti-p38 (9212) and Anti-pp38 T180/Y182 (4511) antibodies were from Cell Signaling Technologies. Anti-GAPDH (LK9002T) antibodies were from Tianjin Sungene Biotech.

**MTT Assay**

Cells were seeded into a 96-well plate at a density of 0.5 × 10^4 cells/well. Then, different concentrations of celastrol (10 µL/well) were added to designated wells. After 72 h, 10 µL of MTT was added to each well at a final concentration of 0.5 mg/ml, and the plate was further incubated for 4 h, allowing viable cells to change the yellow MTT into dark-blue formazan crystals. Subsequently, the medium was discarded and 50 µL of dimethylsulfoxide (DMSO) was added to each well to dissolve the formazan crystals. The absorbance in individual well was determined at 570 nm by multidetection microplate reader 680 (BioRad, PA, USA). The concentrations required to inhibit growth by 50% (IC_{50}) were calculated from survival curves using the Bliss method (17).

**Cell Cycle Analysis**

Cells were harvested and washed twice with cold PBS and then fixed with 70% ice-cold ethanol at 4°C for 30 min. After centrifugation at 200 × g for 10 min, cells were washed twice with PBS, resuspended with 0.5 mL PBS containing PI (50 µg/mL), Triton X-100(0.1%, v/v), 0.1% sodium citrate, and DNase-free RNase (100 µg/mL), and detected by flow cytometry (FCM) after 15 min incubation in the dark at room temperature. Fluorescence was measured at an excitation wave length of 480 nm through a FL-2 filter. Data were analyzed using ModFit LT 3.0 software (Becton Dickinson) (18, 19).

**Apoptosis Analysis**

Cell apoptosis was evaluated with FCM assay. Briefly, cells were harvested and washed twice with cold PBS, then stained with Annexin V-FITC and PI in the binding buffer, and detected by FACS Calibur FCM (BD, CA, USA) after 15 min incubation in

![FIGURE 1](frontiersin.org) | Celastrol inhibited the growth of ovarian cancer cells in vitro. (A) The growth curves, IC_{50} values and (B) phase-contrast images of A2780 and SKOV3 cells treated with the indicated concentrations of celastrol (0, 0.1, 0.3, 1, 3, and 10 µM) for 72 h. Cell survival was measured by MTT assay, and the IC_{50} values of celastrol in each cell lines were calculated.
the dark at room temperature. Fluorescence was measured at an excitation wave length of 480 nm through FL-1 (530 nm) and FL-2 (585 nm) filters. The early apoptotic cells (Annexin V positive only) and late apoptotic cells (Annexin V and PI positive) were quantified (20).

**Western Blot Analysis**

Cells were harvested and washed twice with cold PBS and then resuspended and lysed in RIPA buffer (1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 ng/mL PMSF, 0.03% aprotinin, and 1 µM sodium orthovanadate) at 4°C for 30 min.

FIGURE 2 | Celastrol induced cell cycle arrest in ovarian cancer cells. A2780 and SKOV3 cells were treated with celastrol with the indicated concentrations for 48 h, then cell cycle was detected by FCM. The representative charts (A,C), quantified data (B,D), and Western blot results (E,F) of three independent experiments are shown. *P < 0.05 and **P < 0.01 vs. corresponding control.
FIGURE 3 | Celastrol induced apoptosis in ovarian cancer cells. A2780 and SKOV3 cells were treated with celastrol with the indicated concentrations for 48 h, then cell apoptosis was detected by FCM. The representative charts (A,C), quantified data (B,D), and Western blot results (E,F) of three independent experiments are shown. The same GAPDH image of Figure 2 has been used as loading control. **P < 0.01 vs. corresponding control.
Lysates were centrifuged at 14,000 × g for 10 min and supernatants were collected. Proteins were separated on 12% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% BSA and incubated with the indicated primary antibodies. Corresponding horseradish peroxidase-conjugated secondary antibodies were used against each primary antibody. Proteins were detected using the chemiluminescent detection reagents and films (21, 22).

**Reactive Oxygen Species Assay**

Cells were incubated with 10 µM of DHE at 37°C for 30 min, washed twice with PBS, and microphotographed under a conventional fluorescent microscope (Olympus, Japan) immediately. For each well, 5 fields were taken randomly. Then, cells were rapidly digested, harvested and washed twice with cold PBS, and detected by FCM. The DHE Fluorescence intensity was measured and quantified at an excitation wave length of 518 nm through PE filters (23, 24).

**Nude Mice Xenograft Assay**

Balb/c nude mice were obtained from the Guangdong Medical Laboratory Animal Center and maintained with sterilized food and water. This study was carried out in accordance with the recommendations of the Guidelines for the Care and Use of Laboratory Animals, and the protocol were approved by the Institutional Animal Care and Use Committee of Jinan University. Four female nude mice with 4–5 weeks old and 20–22 g weight were used for each group. Each mouse was treated two ovarian cancer cell lines A2780 and SKOV3 with 0.5% methylcellulose) and celastrol (2 mg/kg) every day. The body weights of mice and the two perpendicular diameters (A (0.5% methylcellulose) and celastrol (2 mg/kg) every day. The body weights of mice and the two perpendicular diameters (A and B) of tumors were recorded every day. The tumor volume (V) was calculated as:

\[ V = \pi/6 \times (1/2(A + B))^3 \]

The mice were anaesthetized after experiment, and tumor tissue was excised from the mice and weighted. The rate of inhibition (IR) was calculated according to the formula:

\[ \text{IR} = 1 - \frac{\text{Mean tumor weight of experimental group}}{\text{Mean tumor weight of control group}} \times 100\% \]

**Statistical Analysis**

A student's t-test was used to compare individual data points between two groups. A P-value of < 0.05 was set as the criterion for statistical significance.

**RESULTS**

**Celastrol Inhibited the Growth of Ovarian Cancer Cells in vitro**

To access the effect of celastrol on ovarian cancer cells, we treated two ovarian cancer cell lines A2780 and SKOV3 with the increasing concentrations of celastrol range from 0.1 to 10 µM for 72 h. As shown in Figures 1A,B, the results of MTT assay revealed that the growth of two ovarian cancer cell lines was similarly inhibited by celastrol in a dose-dependent manner with the IC_{50} values were 2.11 and 2.29 µM in A2780 and SKOV3 respectively. These data suggested that celastrol inhibits the growth of ovarian cancer cells.

**Celastrol Induced Cell Cycle Arrest in Ovarian Cancer Cells**

To determine whether celastrol is able to induce cell cycle arrest, cell cycle distribution was examined after celastrol treatment. A2780 and SKOV3 cells were treated with 0.3, 1 and 3 µM of celastrol for 48 h, then stained with PI and examined by FCM. As shown in Figures 2A–D, celastrol induced the accumulation in Sub G1 and G2/M phase and reduction in G0/G1 and S phase in two ovarian cancer cell lines. Next, the cell cycle related proteins were detected by Western blot. As shown in Figures 2E,F, increased p27 and Cyclin B1 and decreased Cyclin E proteins were detected in celastrol-treated A2780 and SKOV3 cells. Together, these results indicated that celastrol induces cell cycle arrest in ovarian cancer cells.

**Celastrol Induced Apoptosis in Ovarian Cancer Cells**

To determine whether celastrol could induce cell apoptosis, A2780 and SKOV3 cells were treated with indicated concentrations of celastrol for 48 h, apoptosis was assessed by FCM with Annexin V/PI staining. As shown in Figures 3A–D, celastrol dose-dependently induced early stage of apoptosis (Annexin V+/PI−) and late stage of apoptosis (Annexin V+/PI+) in both cells. Treatment of celastrol upregulated the protein expressions of cleaved-PARP, pp38, pJNK T183/Y185 but downregulated the protein expressions of pERK T202/Y204, pAKT S473 and RAF1 (Figures 3E,F). Consequently, these results suggest that celastrol induces cell apoptosis in ovarian cancer cells.

**ROS Generation Was Critical for Celastrol-Induced Apoptosis in Ovarian Cancer Cells**

Numerous antitumor agents demonstrate antitumor activity via ROS-dependent activation of apoptotic cell death (26, 27). It has previously been reported that the elevated intracellular ROS mediated celastrol-induced apoptosis in several human cancer cells (28). Thus, we surmised that celastrol caused apoptosis in ovarian cancer cells was due to excessive ROS generation. Firstly, the cellular ROS was tagged by DHE fluorescence staining in celastrol-treated cells. As shown in Figure 4, celastrol enhanced the detectable red fluorescent signals of DHE in both A2780 and SKOV3 cells, suggesting the intracellular ROS levels were increased after celastrol treatment. Then we pre-treated A2780 and SKOV3 cells with NAC (a specific ROS scavenger), Celastrol-induced cell apoptosis were totally attenuated by NAC in both ovarian cancer cells.
FIGURE 4 | Celastrol enhanced the intracellular ROS levels in ovarian cancer cells. A2780 and SKOV3 cells were treated with celastrol with indicated times and concentrations, stained with DHE, photographed and quantified respectively under fluorescent microscope and FCM. The representative micrographs (A,C) and quantified results (B,D) were shown. **P < 0.01 vs. corresponding control.

Celastrol Inhibited the Tumor Growth of Ovarian Cancer in Nude Mice

To confirm the antitumor effects of celastrol in vivo, A2780 subcutaneous xenograft tumors were generated in the nude mice. As shown in Figures 6A–E, treatment of celastrol did inhibit the growth of A2780 xenograft tumors with the inhibition ratio of 28.60% by diminishing the tumor volumes and weights. Furthermore, mice body weight in celastrol group was close to that of control group, suggesting that celastrol at the indicated dose did not cause toxicity in mice (Figure 6C).

DISCUSSION

Natural products attract more and more attention in the prevention and treatment of cancer in recent years. Products from the plant *Tripterygium wilfordii*, including celastrol and triptolide, are of special attention because of its superior anti-tumor activities against a variety of cancer types, and therefore are the traditional herb medicines considered to have the most potential in modern cancer therapy. For the treatment of ovarian cancer, triptolide has been shown to inhibit the proliferation, migration and invasion of ovarian cancer in multiple pathways (29–31) and demonstrated to exert efficacy in preclinical models (32). Celastrol has also been reported to induce apoptosis and inhibit proliferation, migration and invasion in ovarian cancer cells in vitro (14, 16), but the mechanism for its anti-tumor effect and the effect of celastrol on the growth of ovarian cancer cells in vivo are not fully understood. In our present study,
we have demonstrated that celastrol mediated dose-dependent anti-growth effects on human ovarian cancer cell lines SKOV3 and A2780. The IC₅₀ value after 72 h treatment with celastrol ranged from 2 to 3 µM in these two human ovarian cancer cell lines, similarly to the IC₅₀ value of celastrol of ovarian cancer in other articles (15, 16). We have also shown that celastrol induced both the early and late stage of apoptosis and cell cycle arrest in G2/M phase with obvious up-regulation of cleaved-PARP, pp38 T180/Y182, pJNK T183/Y185, p27 and Cyclin B1 and down-regulation of pERK T202/Y204, pAKT S473, RAF1 and Cyclin E in a dose-dependent manner. Similar with our results, celastrol can induce the activation of JNK and inactivation of AKT in multiple myeloma cells RPMI-8226 (33), activation of p38 in ovarian cancer cells OVCAR-8 and colorectal cancer
cells SW620 cells (34) and inactivation of ERK in hepatoma cells Hep3B (35). Furthermore, celastrol inhibited the growth of A2780 ovarian cancer subcutaneous xenograft tumors in nude mice by diminishing the tumor volumes and weights, and mice body weight in celastrol group was close to that of control group. These in vitro and in vivo data strongly indicate that celastrol may be an appropriate candidate for treating ovarian cancer.

Biological roles of ROS were intricate and important in cancer cells (36). The intracellular ROS plays a significant role in regulating multifarious cell physiological process such as growth, differentiation, death and so on (37). ROS changes the cellular redox condition, induces DNA damage and influences the activities of tumor suppressor or oncogene, thereby involving in the initiation and progression of cancer (38, 39). Lots of studies have shown that cancer cells normally produce more ROS than normal cells (40). Interestingly, accumulating evidence suggests that cancer cells are more vulnerable to ROS-induced death because they are under the increased oxidative stress (41). A variety of agents like YM155, dinaciclib and triptolide may be selectively toxic to tumor cells because they enhanced intracellular oxidant stress and push these already stressed cells beyond their limitation (24, 38, 42, 43). In addition, previous studies have demonstrated that ROS plays a pivotal role in celastrol-induced apoptosis in multiple cancers, such as colon cancer, liver cancer, osteosarcoma, etc. (9, 28, 44). In this study, we have found that the intracellular ROS levels were increased after celastrol treatment, and pretreated with ROS scavenger NAC totally attenuated celastrol-induced cell apoptosis in ovarian cancer cells. It has been reported that celastrol enhanced the intracellular ROS to induce apoptosis by inhibiting mitochondrial respiratory chain
complex I activity in lung cancer H1299 cells (45). Whether celastrol induces ROS accumulation to trigger apoptosis in the same way in ovarian cancer cells need to be further investigated.

In summary, our data have shown that celastrol induced cell growth inhibition, cell cycle arrest in G2/M phase and apoptosis with the increased intracellular ROS accumulation in ovarian cancer cells in vitro and in vivo. Pretreatment with NAC totally blocked the apoptosis induced by celastrol. Altogether, these findings suggest celastrol is a potential therapeutic agent for treating ovarian cancer.

**AUTHOR CONTRIBUTIONS**

L-NX, NZ, J-YC, ZS, and X-JY designed the experiments, performed the experiments, analyzed the data, and wrote the paper. X-WN, H-HZ, P-PY, Q-WJ, YY, J-RH, M-LY, Z-HX, M-NW, and YL performed the experiments. All authors read and approved the final manuscript.

**FUNDING**

This work was supported by funds from the National Key Research and Development Program of China (No. 2017YFA0505104 to ZS), the National Natural Science Foundation of China (No. 81772540 to ZS and No. 81503293 to X-JY), the Guangdong Natural Science Funds for Distinguished Young Scholar (No. 2014A030306001 to ZS), the Guangdong Special Support Program for Young Talent (No. 2015TQ01R350 to ZS), the Science and Technology Program of Guangdong (No. 2016A050502027 to ZS) and the Science and Technology Program of Guangzhou (No. 201704030058 to ZS), the Zhejiang major disease diagnosis and treatment technology research center (No. JBZX-201803 to X-JY).

**REFERENCES**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* (2018) 68:7–30. doi: 10.3322/caac.21442
2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. (2018) 68:284–96. doi: 10.3322/caac.21456
3. Fields EC, McGuire WP. Radiation treatment in women with ovarian cancer: past, present, and future. *Front Oncol*. (2017) 7:177. doi: 10.3389/fonc.2017.00177
4. Ohman AW, Hasan N, Dinulescu DM. Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. *Front Oncol*. (2014) 4:432. doi: 10.3389/fonc.2014.00432
5. Uttarkar S, Dasse E, Coulbaly A, Steinmann S, Jakobs A, Schomburg C, et al. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. *Blood* (2016) 127:1173–82. doi: 10.1182/blood-2015-09-668632
6. Lin L, Sun Y, Wang D, Zheng S, Zhang J, Zheng C. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelial-mesenchymal transition. *Front Pharmacol*. (2015) 6:320. doi: 10.3389/fphar.2015.00320
7. Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. *Cell* (2015) 161:999–1011. doi: 10.1016/j.cell.2015.05.011
8. Wong KF, Yuan Y, Luk JM. *Tripterygium wilfordii* bioactive compounds as anticancer and anti-inflammatory agents. *Clin Exp Pharmacol Physiol*. (2012) 39:311–20. doi: 10.1111/j.1440-1681.2011.05586.x
9. Jiang QW, Cheng KJ, Mei XL, Qiu JG, Zhang WJ, Xue YQ, et al. Synergistic anticancer effects of triptolide and celastrol, two main bioactive compounds as anti-inflammatory agents. *Int J Oncol*. (2015) 45:1867–79. doi: 10.3892/ijo.2015.2810
10. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. *Cancer Biol Ther*. (2006) 5:39–47.
11. Chen X, Gong L, Ou R, Zheng Z, Chen J, Xie F, et al. Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752. *Gynecol Oncol*. (2016) 140:537–44. doi: 10.1016/j.gyno.2015.12.011
12. Lv M, Qiu JG, Zhang WJ, Jiang QW, Qin WM, Yang Y, et al. Wallichine reverses ABCB1-mediated cancer multidrug resistance. *Am J Transl Res* (2018) 10:696–708.
13. Jannuzzi AT, Kara M, Alpertunga B. Celastrol ameliorates acetaminophen-induced oxidative stress and cytotoxicity in HepG2 cells. *Hum Exp Toxicol*. (2018) 37:742–51. doi: 10.1177/0960327217734622
14. Li X, Wang H, Ding J, Nie S, Wang L, Zhang L, et al. Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. *Eur J Pharmacol*. (2018) 842:146–56. doi: 10.1016/j.ejphar.2018.10.043
15. Wang Z, Zhai Z, Du X. Celastrol inhibits migration and invasion through blocking the NF-kappaB pathway in ovarian cancer cells. *Exp Ther Med*. (2017) 14:819–24. doi: 10.3892/etm.2017.4568 ETM-0-0-4568
16. Zheng H, Li J, Li G, Wang S. Effects of celastrol on enhancing apoptosis of ovarian cancer cells via the downregulation of microRNA21 and the suppression of the PI3K/Akt/NF-kappaB signaling pathway in an in vitro model of ovarian carcinoma. *Mol Med Rep*. (2016) 14:5363-8. doi: 10.3892/mmr.2016.5894
17. Shi Z, Park HR, Du Y, Li Z, Cheng K, Sun SY, et al. Cables1 complex couples survival signaling to the cell death machinery. *Cancer Res*. (2015) 75:147–58. doi: 10.1158/0008-5472.CAN-14-0036
18. Zheng DW, Xue YQ, Li Y, Di JM, Qiu JG, Jiang QW, et al. Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. *Am J Cancer Res* (2016) 6:2476–88.
19. Yang Y, Qiu JG, Li Y, Di JM, Zhang WJ, Jiang QW, et al. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. *Am J Transl Res* (2016) 8:3986-94.
20. Shi Z, Park HR, Du Y, Li Z, Cheng K, Sun SY, et al. Cables1 complex couples survival signaling to the cell death machinery. *Cancer Res*. (2015) 75:147–58. doi: 10.1158/0008-5472.CAN-14-0036
21. Zheng DW, Xue YQ, Li Y, Di JM, Qiu JG, Zhang WJ, et al. Volasertib suppresses the growth of human hepatocellular carcinoma in vitro and in vivo. *Am J Cancer Res* (2016) 6:2476–88.
22. Yang Y, Qiu JG, Li Y, Di JM, Zhang WJ, Jiang QW, et al. Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing. *Am J Transl Res* (2016) 8:3986-94.
23. Xie FF, Pan SS, Ou RY, Zheng ZZ, Huang XJ, Jian MT, et al. Volasertib suppresses tumor growth and potentiates the activity of cisplatin in cervical cancer. *Am J Cancer Res*. (2015) 5:3548–59.
24. Hou LJ, Huang XX, Xu LN, Zhang YY, Zhao N, Ou RY, et al. YM155 enhances docetaxel efficacy in ovarian cancer. *Am J Transl Res*. (2018) 10:696–708.
25. Yuan ML, Li P, Xing ZH, Di JM, Liu H, Yang AK, et al. Inhibition of WEE1 suppresses the tumor growth in laryngeal squamous cell carcinoma. *Front Pharmacol*. (2018) 9:1041. doi: 10.3389/fphar.2018.01041
26. Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel
27. Geng YD, Zhang C, Lei JL, Yu P, Xia YZ, Zhang H, et al. Walsuironod B induces mitochondrial and lysosomal dysfunction leading to apoptotic rather than autophagic cell death via ROS/p53 signaling pathways in liver cancer. *Biochem Pharmacol.* (2017) 142:71–86. doi:10.1016/j.bcp.2017.06.134

28. Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie T, et al. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an *in vitro* and *in vivo* study. *Cell Death Dis.* (2015) 6:1604. doi:10.1038/cddis.2014.543

29. Zhao H, Yang Z, Wang X, Zhang X, Wang M, Wang Y, et al. Triptolide inhibits ovarian cancer cell invasion by repression of matrix metalloproteinase 7 and 19 and upregulation of E-cadherin. *Exp Mol Med.* (2012) 44:633–41. doi:10.3858/emm.2012.44.11.072

30. Wang Y, Liu T, Li H. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer. *J Biomater Sci Polym Ed.* (2016) 27:545–56. doi:10.1080/09205063.2015.1131667

31. Hu H, Huang G, Wang H, Li X, Wang X, Feng Y, et al. Inhibition effect of triptolide on human epithelial ovarian cancer via adjusting cellular immunity and angiogenesis. *Oncol Rep.* (2018) 39:1191–6. doi:10.3892/or.2017.6158

32. Patil S, Lis LG, Schumacker PT, Norris BJ, Morgan ML, Cuellar RA, et al. Phosphonooxymethyl Prodrug of Triptolide: Synthesis, Physicochemical Characterization, and Efficacy in Human Colon Adenocarcinoma and Ovarian Cancer Xenografts. *J Med Chem.* (2015) 58:9334–44. doi:10.1021/acs.jmedchem.5b01329

33. Kannaiyan R, Manu KA, Chen L, Li F, Rajendran P, Subramaniam A, et al. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. *Apoptosis* (2011) 16:1028–41. doi:10.1007/s10495-011-0629-6

34. Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, et al. Upregulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. *Cancer Lett.* (2010) 297:155–64. doi:10.1016/j.canlet.2010.04.030

35. Ma J, Han LZ, Liang H, Mi C, Shi H, Lee JY, et al. Celastrol inhibits the HIF-1alpha pathway by inhibition of mTOR/p70S6K/eIF4E and ERK1/2 phosphorylation in human hepatoma cells. *Oncol Rep.* (2014) 32:235–42. doi:10.3892/or.2014.3211

36. Halliwell B. The antioxidant paradox: less paradoxical now? Br J Clin Pharmacol. (2013) 75:637–44. doi:10.1111/j.1365-2125.2012.04272.x

37. Murphy MP, Holmgren A, Larsson NG, Halliwell B, Chang CJ, Kalyanaraman B, et al. Unraveling the biological roles of reactive oxygen species. *Cell Metab.* (2011) 13:361–6. doi:10.1016/j.cmet.2011.03.010

38. Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS, Gong LH, et al. Cyclosporine-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. *Oncotarget* (2015) 6:14926–39. doi:10.18632/oncotarget.3717

39. Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? *Nat Rev Cancer* (2014) 14:709–21. doi:10.1038/nrc3803

40. Sztroowski TR, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. *Cancer Res* (1991) 51:794–8.

41. Schumacker PT. Reactive oxygen species in cancer cells: live by the sword, die by the sword. *Cancer Cell* (2006) 10:175–6. doi:10.1016/j.ccr.2006.08.015

42. Li R, Jia Z, Trush MA. Defining ROS in biology and medicine. *React Oxygen Species (Apex)* (2016) 1:9–21. doi:10.20455/roa.2016.803

43. Tarafdar S, Chiu GN. Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolide-induced apoptosis. *Int J Oncol.* (2013) 42:1605–12. doi:10.3892/ijo.2013.1843.

44. Liu X, Gao RW, Li M, Si CF, He YP, Wang M, et al. The ROS derived mitochondrial respiration not from NADPH oxidase plays key role in Celastrol against angiotensin II-mediated HepG2 cell proliferation. *Apoptosis* (2016) 21:1315–26. doi:10.1007/s10495-016-1294-6

45. Chen G, Zhang X, Zhao M, Wang Y, Cheng X, Wang D, et al. Celastrol targets mitochondrial respiratory chain complex I to induce reactive oxygen species-dependent cytotoxicity in tumor cells. *BMC Cancer* (2011) 11:170. doi:10.1186/1471-2407-11-170

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Xu, Zhao, Chen, Ye, Nan, Zhou, Jiang, Yang, Huang, Yuan, Xing, Wei, Li, Shi and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.